TY - JOUR
T1 - Pharmacological effects of methylone and MDMA in humans
AU - Poyatos, Lourdes
AU - Pérez-Mañá, Clara
AU - Hladun, Olga
AU - Núñez-Montero, Melani
AU - de la Rosa, Georgina
AU - Martín, Soraya
AU - Barriocanal, Ana Maria
AU - Carabias, Lydia
AU - Kelmendi, Benjamin
AU - Taoussi, Omayema
AU - Busardò, Francesco Paolo
AU - Fonseca, Francina
AU - Torrens, Marta
AU - Pichini, Simona
AU - Farré, Magí
AU - Papaseit, Esther
N1 - Publisher Copyright:
Copyright © 2023 Poyatos, Pérez-Mañá, Hladun, Núñez-Montero, de la Rosa, Martín, Barriocanal, Carabias, Kelmendi, Taoussi, Busardò, Fonseca, Torrens, Pichini, Farré and Papaseit.
PY - 2023/2/17
Y1 - 2023/2/17
N2 - Methylone is one of the most common synthetic cathinones popularized as a substitute for 3,4-methylenedioxymethamphetamine (MDMA, midomafetamine) owing to its similar effects among users. Both psychostimulants exhibit similar chemistry (i.e., methylone is a β-keto analog of MDMA) and mechanisms of action. Currently, the pharmacology of methylone remains scarcely explored in humans. Herein, we aimed to evaluate the acute pharmacological effects of methylone and its abuse potential in humans when compared with that of MDMA following oral administration under controlled conditions. Seventeen participants of both sexes (14 males, 3 females) with a previous history of psychostimulant use completed a randomized, double-blind, placebo-controlled, crossover clinical trial. Participants received a single oral dose of 200 mg of methylone, 100 mg of MDMA, and a placebo. The variables included physiological effects (blood pressure, heart rate, oral temperature, pupil diameter), subjective effects using visual analog scales (VAS), the short form of the Addiction Research Center Inventory (ARCI), the Evaluation of Subjective Effects of Substances with Abuse Potential questionnaire (VESSPA-SSE), and the Sensitivity to Drug Reinforcement Questionnaire (SDRQ), and psychomotor performance (Maddox wing, psychomotor vigilance task). We observed that methylone could significantly increase blood pressure and heart rate and induce pleasurable effects, such as stimulation, euphoria, wellbeing, enhanced empathy, and altered perception. Methylone exhibited an effect profile similar to MDMA, with a faster overall onset and earlier disappearance of subjective effects. These results suggest that abuse potential of methylone is comparable to that of MDMA in humans. Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT05488171; Identifier: NCT05488171.
AB - Methylone is one of the most common synthetic cathinones popularized as a substitute for 3,4-methylenedioxymethamphetamine (MDMA, midomafetamine) owing to its similar effects among users. Both psychostimulants exhibit similar chemistry (i.e., methylone is a β-keto analog of MDMA) and mechanisms of action. Currently, the pharmacology of methylone remains scarcely explored in humans. Herein, we aimed to evaluate the acute pharmacological effects of methylone and its abuse potential in humans when compared with that of MDMA following oral administration under controlled conditions. Seventeen participants of both sexes (14 males, 3 females) with a previous history of psychostimulant use completed a randomized, double-blind, placebo-controlled, crossover clinical trial. Participants received a single oral dose of 200 mg of methylone, 100 mg of MDMA, and a placebo. The variables included physiological effects (blood pressure, heart rate, oral temperature, pupil diameter), subjective effects using visual analog scales (VAS), the short form of the Addiction Research Center Inventory (ARCI), the Evaluation of Subjective Effects of Substances with Abuse Potential questionnaire (VESSPA-SSE), and the Sensitivity to Drug Reinforcement Questionnaire (SDRQ), and psychomotor performance (Maddox wing, psychomotor vigilance task). We observed that methylone could significantly increase blood pressure and heart rate and induce pleasurable effects, such as stimulation, euphoria, wellbeing, enhanced empathy, and altered perception. Methylone exhibited an effect profile similar to MDMA, with a faster overall onset and earlier disappearance of subjective effects. These results suggest that abuse potential of methylone is comparable to that of MDMA in humans. Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT05488171; Identifier: NCT05488171.
KW - 3,4-methylenedioxymethamphetamine
KW - 3,4-methylenedioxymethcathinone
KW - bath salts
KW - MDMA
KW - methylone
KW - new psychoactive substances
KW - psychostimulants
KW - synthetic cathinones
UR - http://www.scopus.com/inward/record.url?scp=85149947900&partnerID=8YFLogxK
U2 - 10.3389/fphar.2023.1122861
DO - 10.3389/fphar.2023.1122861
M3 - Article
C2 - 36873994
AN - SCOPUS:85149947900
SN - 1663-9812
VL - 14
SP - 1122861
JO - Frontiers in Pharmacology
JF - Frontiers in Pharmacology
M1 - 1122861
ER -